Please assess the completion status of the following clinical trial:

Trial Title: Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo, in Patients With Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Ages eligible for study: 12 years and above; genders eligible for study: both; prior steroid use: steroid-requiring or steroid-free.~Inclusion Criteria:~* History of asthma for at least 12 months.~* For steroid-requiring patients, documented use of inhaled corticosteroid for at least 4 weeks prior to Screening Visit~* For steroid-free patients, no history of inhaled steroid asthma medication for at least 12 weeks prior to Screening Visit.~* Demonstrate FEV-1 of 60-85% of predicted normal values at Screening and Baseline Visit.~* Documented reversibility of 15% within 12 months of Screening or at Screening Visit (15% increase from pre-FEV-1 levels following albuterol inhalation or nebulized albuterol administration).~* Symptoms of Asthma during Run-in~* Females of childbearing potential must have a negative urine pregnancy test at Screening and Baseline Visits. Females are eligible only if they are not pregnant or lactating, and are either sterile, or using acceptable methods of contraception.~* Must otherwise be healthy.~* Provide written informed consent. Wishes of minors must be respected.~Exclusion Criteria:~* Life-threatening asthma within past year or during Run-In Period.~* History of systemic corticosteroid medication within 3 months before Screening Visit.~* History of omalizumab use within past 6 months.~* History of leukotriene receptor antagonist use, e.g. montelukast, within past week.~* Current evidence or history of any clinically significant disease or abnormality including uncontrolled hypertension, uncontrolled coronary artery disease, congestive heart failure, myocardial infarction, or cardiac dysrhythmia.~* Upper or lower respiratory infection within 4 weeks prior to Screening Visit or during Run-In Period.~* Significant, non-reversible, pulmonary disease (e.g., chronic obstructive pulmonary disease \[COPD\], cystic fibrosis, bronchiectasis).~* Known Human Immunodeficiency Virus (HIV)-positive status.~* Smoking history equivalent to 10 pack years.~* Current smoking history within 12 months prior to Screening Visit.~* Current evidence or history of alcohol and/or substance abuse within 12 months prior to Screening Visit.~* Patients who are confined in institution

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): FlutiForm 100/10 μg
- 2 (Type: ACTIVE_COMPARATOR): Fluticasone 100 μg
- 3 (Type: ACTIVE_COMPARATOR): Formoterol 10 μg
- 4 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).